A Prospective, Randomized, Open-label Phase III Clinical Study of the Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy Versus Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Fuzuloparib (Primary) ; Abemaciclib; Anastrozole; Exemestane; Goserelin; Letrozole; Leuprorelin; Tamoxifen; Toremifene
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 13 Nov 2023 Status changed from not yet recruiting to recruiting.
- 28 Jul 2023 New trial record